- Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development - Elacestrant further strengthens Menarini's global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S. - Radius will receive $30M as an upfront payment and up to $320M in additional milestones along with tiered low to mid-teen percentage royalties The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced
Betagro Expands Its Footprint in Singapore with THB 1.9 Billion Acquisition of Eggriculture to Drive Sustainable Growth
—
Betagro Public Company Limited (...
SCGP Completed the Acquisition of 70% Stake in Starprint Vietnam JSC, Advancing the Footprint in Premium Offset Folding Carton Packaging in ASEAN
—
SCGP has ac...
EGCO Group Acquires 30% Interest in Infrastructure and Utility Business in Indonesia
—
Electricity Generating Public Company Limited or EGCO Group has str...
Volvo Trucks delivered 14 Volvo FH to Wattanakol Transports for an Ambitious Cross-Border Project
—
Wattanakol Transports 2001 Co., Ltd., a prominent play...
Rabbit LINE Pay Announces Rebranding to LINE Pay Payment Services Continue as Usual
—
Rabbit LINE Pay, leading integrated online and offline payment platf...
Krungsri makes notable advances in ASEAN, with the successful acquisition of Home Credit in Indonesia
—
Krungsri (Bank of Ayudhya PCL) announced the succe...